Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-03-01
DOI
10.3389/fimmu.2018.00394
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
- (2017) Mérédis Favreau et al. HAEMATOLOGICA
- Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
- (2017) Maria Carmen Ochoa et al. IMMUNOLOGY AND CELL BIOLOGY
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells
- (2017) Mariolina Salio et al. JOURNAL OF IMMUNOLOGY
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle
- (2017) Peng Zhao et al. MOLECULAR PHARMACEUTICS
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis
- (2017) Y. Ding et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
- (2017) Abhishek D. Garg et al. TRENDS IN IMMUNOLOGY
- Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
- (2017) Massimo Giuliani et al. Oncotarget
- Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
- (2017) Mérédis Favreau et al. HAEMATOLOGICA
- Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion
- (2017) Johan M.J. Van den Bergh et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential
- (2017) Christian W. Keller et al. Frontiers in Immunology
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
- (2017) Zijun Y. Xu-Monette et al. Frontiers in Immunology
- PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
- (2017) Carmen Stecher et al. Frontiers in Immunology
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Trial watch: Dendritic cell-based anticancer immunotherapy
- (2017) Abhishek D. Garg et al. OncoImmunology
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Dendritic Cell Therapies for Hematologic Malignancies
- (2017) Matthew Weinstock et al. Molecular Therapy-Methods & Clinical Development
- Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
- (2017) Fei Zhang et al. Cell Discovery
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Combination of DC Vaccine and Conventional Chemotherapeutics
- (2016) Wei Dong et al. Anti-Cancer Agents in Medicinal Chemistry
- Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model
- (2016) Lydia Dyck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
- (2016) Toshiko Kamata et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
- (2016) K. F. Bol et al. CLINICAL CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor
- (2016) Seth B. Coffelt et al. IMMUNITY
- Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity
- (2016) Deshapriya S. Karunarathne et al. IMMUNITY
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- NK Cells Restrain Spontaneous Antitumor CD8+T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells
- (2016) Ximena L. Raffo Iraolagoitia et al. JOURNAL OF IMMUNOLOGY
- Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
- (2016) Jingwei Liu et al. JOURNAL OF IMMUNOTHERAPY
- Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
- (2016) J. Rosenblatt et al. Science Translational Medicine
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish Immune Tolerance in Transplantation
- (2016) Chao Zhang et al. Journal of Immunology Research
- Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
- (2016) Lien Vandenberk et al. Frontiers in Immunology
- The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
- (2016) Chunwan Lu et al. OncoImmunology
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice
- (2015) Anniek B. van der Waart et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Human dendritic cell subsets and function in health and disease
- (2015) Meredith O’Keeffe et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Programmed death-1 checkpoint blockade in acute myeloid leukemia
- (2015) Alison Sehgal et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nivolumab: targeting PD-1 to bolster antitumor immunity
- (2015) Julie R Brahmer et al. Future Oncology
- Programmed death-1 & its ligands: promising targets for cancer immunotherapy
- (2015) Rajeev K Shrimali et al. Immunotherapy
- PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity
- (2015) Saeed Daneshmandi et al. Immunotherapy
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18
- (2015) Mieke W.H. Roeven et al. JOURNAL OF IMMUNOTHERAPY
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma
- (2015) Guang-Tao Yu et al. Oncotarget
- CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy
- (2015) Lena M Kranz et al. Human Vaccines & Immunotherapeutics
- Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
- (2015) Sérgio T. Ribeiro et al. Frontiers in Immunology
- Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
- (2015) Jashodeep Datta et al. Frontiers in Immunology
- Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots
- (2015) Gabriela Andrea Pizzurro et al. Frontiers in Immunology
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
- (2015) Heleen H Van Acker et al. OncoImmunology
- 29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
- (2015) Arthur A Hurwitz et al. Journal for ImmunoTherapy of Cancer
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
- (2015) Bo Yuan Huang et al. PLoS One
- PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
- (2015) Anne-Marit Sponaas et al. PLoS One
- MAIT Cell Function is Modulated by PD-1 Signaling in Patients with Active Tuberculosis
- (2014) Jing Jiang et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation
- (2014) Rachel M. Gibbons et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
- (2014) Jasper J. P. van Beek et al. CRITICAL REVIEWS IN IMMUNOLOGY
- Dendritic cells and cancer immunotherapy
- (2014) Kristen J Radford et al. CURRENT OPINION IN IMMUNOLOGY
- Dendritic cell vaccination in acute myeloid leukemia
- (2014) Sébastien Anguille et al. CYTOTHERAPY
- Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
- (2014) Kent Shih et al. DRUGS
- Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells
- (2014) Víctor G. Martínez et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy
- (2014) Simone Muenst et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells
- (2014) J J Pen et al. GENE THERAPY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells
- (2014) Shasha Song et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy
- (2014) Jacek Rolinski et al. Journal of Immunotoxicology
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- Clinical use of dendritic cells for cancer therapy
- (2014) Sébastien Anguille et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Mitigating the toxic effects of anticancer immunotherapy
- (2014) Tara C. Gangadhar et al. Nature Reviews Clinical Oncology
- Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro
- (2014) Shuo Wang et al. OncoTargets and Therapy
- Engineering better immunotherapies via RNA interference
- (2014) Mouldy Sioud Human Vaccines & Immunotherapeutics
- Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
- (2013) Yan Ge et al. CANCER LETTERS
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Exploiting dendritic cells in the development of cancer vaccines
- (2013) Laura Bracci et al. Expert Review of Vaccines
- Negative role of inducible PD-1 on survival of activated dendritic cells
- (2013) S. J. Park et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34+ Hematopoietic Progenitor Cells
- (2013) Soley Thordardottir et al. STEM CELLS AND DEVELOPMENT
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
- (2013) Angela Vasaturo et al. Frontiers in Immunology
- Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
- (2013) Christel Devaud et al. OncoImmunology
- Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation
- (2012) Willemijn Hobo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cytotoxic Activity of Dendritic Cells as a Possible Mechanism of Negative Regulation of T Lymphocytes in Pulmonary Tuberculosis
- (2012) Ludmila V. Sakhno et al. Clinical & Developmental Immunology
- Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model
- (2012) Xiufen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation
- (2012) W. Hobo et al. JOURNAL OF IMMUNOLOGY
- PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines
- (2012) Bingbing Dai et al. MOLECULAR THERAPY
- NK Cells: Key to Success of DC-Based Cancer Vaccines?
- (2012) E. Lion et al. ONCOLOGIST
- TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation
- (2012) XIAO YAN NI et al. ONCOLOGY REPORTS
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
- (2012) Sonia Norris et al. VIRAL IMMUNOLOGY
- The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
- (2011) Jurjen Tel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
- (2011) Kevin Durgan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prospects for TIM3-Targeted Antitumor Immunotherapy
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
- (2011) M. Terme et al. CANCER RESEARCH
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
- (2011) W. Joost Lesterhuis et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
- (2011) J. Krempski et al. JOURNAL OF IMMUNOLOGY
- Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
- (2011) Mi-Young Song et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
- (2011) Thomas Schneider et al. Journal of Thoracic Oncology
- Engineering Dendritic Cells to Enhance Cancer Immunotherapy
- (2011) Jeanette E Boudreau et al. MOLECULAR THERAPY
- siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells
- (2010) W. Hobo et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
- (2010) W J Lesterhuis et al. BRITISH JOURNAL OF CANCER
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response
- (2010) A. Reschner et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens
- (2010) Masashi Iwasaki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The evolving role of dendritic cells in cancer therapy
- (2010) EJ Ilett et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Enhancement of dendritic cells as vaccines for cancer
- (2010) Meghan E Turnis et al. Immunotherapy
- APCs Expressing High Levels of Programmed Death Ligand 2 Sustain the Development of CD4 T Cell Memory
- (2010) J. S. Ellis et al. JOURNAL OF IMMUNOLOGY
- Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization
- (2010) Q. Zhou et al. JOURNAL OF IMMUNOLOGY
- Role Played by the Programmed Death‐1–Programmed Death Ligand Pathway during Innate Immunity againstMycobacterium tuberculosis
- (2010) Ivana B. Alvarez et al. JOURNAL OF INFECTIOUS DISEASES
- Dendritic Cells in Chronic Mycobacterial Granulomas Restrict Local Anti-Bacterial T Cell Response in a Murine Model
- (2010) Heidi A. Schreiber et al. PLoS One
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
- (2010) V. F. Van Tendeloo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L2 induction on dendritic cells exposed to Mycobacterium avium downregulates BCG-specific T cell response
- (2010) Elizabeth Mendoza-Coronel et al. TUBERCULOSIS
- Directing dendritic cell immunotherapy towards successful cancer treatment
- (2009) Rachel Lubong Sabado et al. Immunotherapy
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination
- (2009) V. Pulko et al. JOURNAL OF IMMUNOLOGY
- B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells
- (2009) Wei Ge et al. LEUKEMIA RESEARCH
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
- (2008) S. Sauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now